Why Fighting Aging-Related Diseases Pays Off More the More We Do It

For more than half a century, the way public health researchers think about the changing burdens of disease has been organized around a single powerful idea: the epidemiological transition. First articulated in the early 1970s, the concept describes how societies move from a world dominated by infectious diseases, famines, and high infant mortality to one dominated by chronic, non-communicable conditions such as heart disease, cancer, and dementia. The transition has traditionally been narrated as a sequence of stages, each with its characteristic pattern of mortality, and the implicit message has often been a grim trade-off: as people survive longer, they simply accumulate more chronic illness, and medicine trades one burden for another. A provocative new perspective published in Nature Aging argues that this framing is not only outdated but actively misleading, obscuring the most important economic and medical fact about aging-related diseases today.

The new analysis, led by researchers working at the intersection of demography, gerontology, and health economics, proposes that the epidemiological transition should be reinterpreted through the lens of increasing returns. In economics, a process exhibits increasing returns when each additional unit of effort or investment yields proportionally greater benefits, at least over a relevant range. Classical public health problems often display the opposite property, diminishing returns: the first doses of a vaccine or the first clean water systems deliver enormous gains, but as coverage approaches completeness, each marginal improvement costs more and buys less. Infectious disease control, malaria eradication, and even tobacco taxation eventually run into this wall of diminishing marginal benefit. Aging-related diseases, the authors argue, behave in precisely the reverse manner.

The empirical foundation for this claim comes from a systematic reframing of the global disease burden by the age at which conditions occur. Rather than grouping diseases by their biological system, their mode of transmission, or their chronicity, the researchers sorted conditions by whether and when they arise along the human lifespan, with a particular focus on those whose incidence rises steeply with age. When the global burden of disease is sliced this way, a striking pattern emerges: aging-related diseases now dominate the total health burden not only in wealthy nations such as Japan, Germany, and the United States, but in every income group, including low- and middle-income countries that are still contending with substantial infectious disease loads. This dominance is not a distant projection; it is the present reality of global health.

This finding alone is significant, because it dismantles a persistent assumption in global health policy that chronic, aging-related conditions are a problem that can be deferred until after the infectious disease agenda is complete. The data show that there is no queue. Countries do not graduate from infection to aging-related illness in a tidy sequence; instead, aging-related diseases have already overtaken every other category of disease burden worldwide, even where HIV, tuberculosis, and malaria remain serious concerns. Policymakers who continue to treat aging-related diseases as a rich-country preoccupation are, in effect, planning for a world that no longer exists. The double burden of disease that many nations face is not transitional but structural, and the aging-related component of that burden is the larger half.

The deeper novelty of the paper, however, lies in its economic characterization of these diseases. The authors identify what they describe as a unique and underappreciated property: aging-related diseases exhibit increasing returns to tackling them. The more a society invests in preventing, delaying, or treating the conditions of aging, the greater the gains it reaps, not merely in aggregate but at the margin. The reasoning follows from the interconnected biology of aging itself. Aging is the single largest risk factor for a vast constellation of conditions, including cardiovascular disease, most cancers, Alzheimer’s disease and other dementias, type 2 diabetes, osteoporosis, macular degeneration, and frailty. These conditions do not occur independently; they share upstream mechanisms, from cellular senescence and chronic inflammation to mitochondrial dysfunction, stem cell exhaustion, and the accumulation of molecular damage across the genome and proteome.

Because these mechanisms are shared, progress against one aging-related disease tends to make progress against others easier and more valuable. Targeting the biology of aging directly, for example by clearing senescent cells, modulating nutrient-sensing pathways, or extending healthspan through interventions validated in model organisms, can reduce risk across multiple disease categories simultaneously. Each success compounds the value of the next. A therapy that delays aging by even a modest margin would delay the onset of nearly every chronic disease at once, an effect that researchers have estimated could be worth tens of trillions of dollars in health and economic value for the United States alone, and proportionally more at the global scale. Unlike single-disease campaigns that exhaust the easiest gains first, geroscience-informed interventions improve the substrate on which all subsequent medical progress operates, so the marginal benefit of additional effort rises rather than falls.

The reframing also has profound implications for how the success of the epidemiological transition should be measured. In the classical account, the compression of morbidity, shortening the period of illness at the end of life, has proven difficult to achieve, and many observers have concluded that longer lives necessarily mean longer periods of chronic disease. The increasing-returns perspective offers a different account: the health challenges of extended lifespans are not an inevitable consequence of success against infectious disease, but a solvable problem whose difficulty actually decreases as investment grows. Delaying aging compresses morbidity by shifting the onset of multiple diseases later and often faster than it extends the final period of severe illness. Populations with longer healthspans are also more productive, more independent, and less costly to health systems, generating fiscal returns that reinforce the original investment, a virtuous cycle that diminishing-returns diseases cannot offer.

The authors are careful to note that recognizing increasing returns does not mean neglecting infectious diseases, maternal health, or childhood conditions, which still demand sustained investment and where coverage gaps remain a moral and practical emergency. Rather, the argument is about prioritization and framing. If aging-related diseases dominate the global burden in every income group, and if they uniquely reward additional effort with accelerating gains, then the current allocation of research funding, which still directs the overwhelming majority of biomedical resources toward individual late-stage diseases rather than the shared biology of aging, looks difficult to defend. Treating each chronic disease in isolation, the paper suggests, is analytically equivalent to treating each symptom of a single systemic condition as a separate ailment, fragmenting effort precisely where integration would be most rewarded.

The practical agenda that follows is ambitious but concrete. It includes accelerating the translation of geroscience discoveries, such as senolytic drugs, metformin and rapamycin analogues, and other interventions that target aging mechanisms, into large-scale clinical trials designed around aging itself rather than around individual end-stage diseases. It includes regulatory reform, since agencies currently lack approval pathways for therapies whose indication is aging rather than a named disease. And it includes a demographic and economic research program that treats healthspan extension as measurable infrastructure, with returns that can be quantified, projected, and incorporated into national planning. Countries that move early, the analysis implies, will capture compounding advantages in workforce productivity, healthcare sustainability, and healthy longevity that late movers will struggle to match.

What emerges from this reframing is a fundamentally more hopeful story than the one embedded in the traditional epidemiological transition. Longer lives are not a Pyrrhic victory that simply swaps infectious scourges for chronic suffering. They are the precondition for a form of medical progress whose returns increase with scale: every year of delayed aging reduces the burden of many diseases at once, strengthens the case for further investment, and raises the ceiling of what future interventions can achieve. The transition that global health has already made, from a world of early death to a world of long life, has created the conditions for a second transition, from treating the diseases of aging one by one to addressing their shared roots. Recognizing that this second transition offers increasing rather than diminishing returns may prove to be one of the most consequential ideas in modern public health.

Subject of Research: Reframing the epidemiological transition as increasing returns to tackling aging-related diseases

Article Title: Reframing the epidemiological transition as increasing returns to tackling aging-related diseases

Article References: Ashwin, J., Bloom, D. E., Lee, N., Piot, P., & Scott, A. J. (2026). Reframing the epidemiological transition as increasing returns to tackling aging-related diseases. Nature Aging. https://doi.org/10.1038/s43587-026-01210-2

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01210-2

Keywords: epidemiological transition, aging-related diseases, global burden of disease, geroscience, increasing returns, healthspan, non-communicable diseases, biology of aging, health economics, longevity, public health policy, compression of morbidity